In the past week, ABVX stock has gone down by -6.99%, with a monthly decline of -16.36% and a quarterly plunge of -20.58%. The volatility ratio for the week is 4.77%, and the volatility levels for the last 30 days are 4.05% for Abivax ADR The simple moving average for the past 20 days is -10.58% for ABVX’s stock, with a -19.66% simple moving average for the past 200 days.
Is It Worth Investing in Abivax ADR (NASDAQ: ABVX) Right Now?
Additionally, the 36-month beta value for ABVX is 0.38. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 2 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ABVX is 55.03M and currently, short sellers hold a 0.38% ratio of that float. The average trading volume of ABVX on October 03, 2024 was 83.05K shares.
ABVX) stock’s latest price update
The stock price of Abivax ADR (NASDAQ: ABVX) has dropped by -5.38 compared to previous close of 10.97. Despite this, the company has seen a fall of -6.99% in its stock price over the last five trading days. globenewswire.com reported 2024-09-26 that Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024 Professor Bruce E. Sands, MD to present oral presentation of Phase 2b, open-label, maintenance efficacy and safety data at weeks 48 and 96 among week 8 induction non-responders in obefazimod-treated patients with moderately to severely active ulcerative colitis (UC) Two moderated poster presentations highlighting corticosteroid-free efficacy and safety data of obefazimod at weeks 48 and 96 of an open-label maintenance trial, as well as the impact of obefazimod induction therapy on combined histologic and endoscopic outcomes at week 8 in patients with UC PARIS, France, September 26, 2024 – 08:30 a.m.
Analysts’ Opinion of ABVX
Many brokerage firms have already submitted their reports for ABVX stocks, with Laidlaw repeating the rating for ABVX by listing it as a “Buy.” The predicted price for ABVX in the upcoming period, according to Laidlaw is $48 based on the research report published on July 29, 2024 of the current year 2024.
BTIG Research, on the other hand, stated in their research note that they expect to see ABVX reach a price target of $43. The rating they have provided for ABVX stocks is “Buy” according to the report published on May 20th, 2024.
Piper Sandler gave a rating of “Overweight” to ABVX, setting the target price at $42 in the report published on April 29th of the current year.
ABVX Trading at -10.57% from the 50-Day Moving Average
After a stumble in the market that brought ABVX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -39.01% of loss for the given period.
Volatility was left at 4.05%, however, over the last 30 days, the volatility rate increased by 4.77%, as shares sank -15.33% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -13.79% lower at present.
During the last 5 trading sessions, ABVX fell by -6.99%, which changed the moving average for the period of 200-days by -0.67% in comparison to the 20-day moving average, which settled at $11.51. In addition, Abivax ADR saw -2.99% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for ABVX
The total capital return value is set at -0.51. Equity return is now at value -171.78, with -78.06 for asset returns.
Based on Abivax ADR (ABVX), the company’s capital structure generated 0.22 points at debt to capital in total, while cash flow to debt ratio is standing at -1.81. The debt to equity ratio resting at 0.28. The interest coverage ratio of the stock is -6.47.
Currently, EBITDA for the company is -131.29 million with net debt to EBITDA at 1.5. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.04.
Conclusion
In conclusion, Abivax ADR (ABVX) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
